RedHill Biopharma announced that it received confirmation from The Nasdaq Stock Market that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on December 8, 2023.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDHL:
- RedHill Biopharma announces new non-dilutive external funding
- Biotech Alert: Searches spiking for these stocks today
- RedHill Biopharma announces FDA grant of 5-year market exclusivity for Talicia
- RedHill Biopharma to transfer listing to Nasdaq Capital Market
- RedHill Biopharma files to sell 8.86M American Depositary Shares for holders